C
Caroline Hervé
Researcher at UCB
Publications - 20
Citations - 719
Caroline Hervé is an academic researcher from UCB. The author has contributed to research in topics: Zoster vaccine & Vaccination. The author has an hindex of 8, co-authored 20 publications receiving 372 citations. Previous affiliations of Caroline Hervé include GlaxoSmithKline.
Papers
More filters
Journal ArticleDOI
The how’s and what’s of vaccine reactogenicity
Caroline Hervé,Béatrice Laupèze,Giuseppe Del Giudice,Arnaud Didierlaurent,Fernanda Tavares Da Silva +4 more
TL;DR: The intent is to provide an overview of reactogenicity after vaccination to help the vaccine community in maintaining confidence in vaccines by promoting vaccination, setting expectations for vaccinees about what might occur after vaccination and reducing anxiety by managing the vaccination setting.
Journal ArticleDOI
Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.
Margherita Coccia,Catherine Collignon,Caroline Hervé,Aurélie Chalon,Iain Welsby,Sophie Detienne,Mary J. van Helden,Sheetij Dutta,Christopher J. Genito,Norman C. Waters,Katrijn Van Deun,Katrijn Van Deun,Age K. Smilde,Robert A. van den Berg,David Franco,Patricia Bourguignon,Sandra Morel,Nathalie Garçon,Bart N. Lambrecht,Stanislas Goriely,Robbert van der Most,Arnaud M. Didierlaurent +21 more
TL;DR: In this article, the authors reported a unique mechanism of molecular and cellular synergy between a TLR4 ligand, 3-Odesacyl-4'-monophosphoryl lipid A (MPL), and a saponin, QS-21, the constituents of the Adjuvant System AS01.
Journal ArticleDOI
Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled study
Lynette Denny,Bronwyn Hendricks,Chivaugn Gordon,Florence Thomas,Marjan Hezareh,Kurt Dobbelaere,Christelle Durand,Caroline Hervé,Dominique Descamps +8 more
TL;DR: The HPV-16/18 AS04-adjuvanted vaccine appears immunogenic and well-tolerated in women with HIV infection, and no impact of baseline CD4⁺ T-cell count or HIV viral load was observed on the magnitude of the immune response in HIV-positive women.
Journal ArticleDOI
Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood.
TL;DR: A historical perspective on how AS were developed from the angle of the challenges encountered on safety evaluation during clinical development and after licensure is provided, and how these challenges have been met to date are illustrated.
Journal ArticleDOI
Superior antigen-specific CD4+T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older
Robert B. Couch,José M. Bayas,Covadonga Caso,Innocent N. Mbawuike,Concepción Núñez López,Carine Claeys,Mohamed El Idrissi,Caroline Hervé,Béatrice Laupèze,Lidia Oostvogels,Philippe Moris +10 more
TL;DR: This positive effect of AS03 Adjuvant System on the CD4+ T-cell response to influenza vaccine strains in older adults could confer benefit in protection against clinical influenza disease in this population.